Pfizer to Acquire Metsera to Advance Obesity and Cardiometabolic Drug Pipeline
Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfoli…
